These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8936438)

  • 41. Takings issues in the approval of generic biologics.
    Yoo JC
    Food Drug Law J; 2005; 60(1):33-43. PubMed ID: 15940853
    [No Abstract]   [Full Text] [Related]  

  • 42. Status of certain additional over-the-counter drug category II and III active ingredients. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 May; 67(90):31125-7. PubMed ID: 12001972
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sanofi Pharmaceuticals, Inc., et al.; withdrawal of approval of 21 new drug applications and 62 abbreviated new drug applications--FDA. Notice.
    Fed Regist; 1998 May; 63(91):26191-3. PubMed ID: 10179336
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Digoxin products for oral use; revocation of conditions for marketing. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Jun; 67(123):42992-7. PubMed ID: 12120661
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Managed care implications of the approval of generic or over-the-counter nonsedating antihistamines.
    Giaquinta D
    Manag Care Interface; 2002 Jun; 15(6):31-4. PubMed ID: 12087604
    [No Abstract]   [Full Text] [Related]  

  • 46. Drug advisory committees. Getting outside advice for close calls.
    Farley D
    FDA Consum; 1995 Mar; 29(2):23-6. PubMed ID: 10172354
    [No Abstract]   [Full Text] [Related]  

  • 47. The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology.
    McKee AE; Farrell AT; Pazdur R; Woodcock J
    Oncologist; 2010; 15 Suppl 1():13-8. PubMed ID: 20237212
    [TBL] [Abstract][Full Text] [Related]  

  • 48. "Counter" intuitive.
    Weinberg JM
    Cutis; 2005 May; 75(5):261. PubMed ID: 15984624
    [No Abstract]   [Full Text] [Related]  

  • 49. A sad day for science at the FDA.
    Burstein PD
    N Engl J Med; 2005 Dec; 353(24):2619-21; author reply 2619-21. PubMed ID: 16354903
    [No Abstract]   [Full Text] [Related]  

  • 50. FDA regulation of OTC oral health care drug products.
    Rippere JL
    J Public Health Dent; 1992; 52(6):329-32. PubMed ID: 1432917
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Waiting for plan B--the FDA and nonprescription use of emergency contraception.
    Steinbrook R
    N Engl J Med; 2004 Jun; 350(23):2327-9. PubMed ID: 15175432
    [No Abstract]   [Full Text] [Related]  

  • 52. Pot in palliative care: what we need to know.
    Strouse TB
    J Palliat Med; 2015 Jan; 18(1):7-10. PubMed ID: 25420209
    [No Abstract]   [Full Text] [Related]  

  • 53. The FDA, politics, and plan B.
    Burstein PD
    N Engl J Med; 2004 Jun; 350(23):2413-4; author reply 2413-4. PubMed ID: 15175445
    [No Abstract]   [Full Text] [Related]  

  • 54. Emergency contraception: politics trumps science at the U.S. Food and Drug Administration.
    Iffy L
    Obstet Gynecol; 2004 Nov; 104(5 Pt 1):1103-4; author reply 1104. PubMed ID: 15516409
    [No Abstract]   [Full Text] [Related]  

  • 55. The issue of extralabel drug use.
    Kennedy JA
    J Am Vet Med Assoc; 1997 Dec; 211(11):1354. PubMed ID: 9394877
    [No Abstract]   [Full Text] [Related]  

  • 56. Marketing drugs too early in testing.
    Begg CB; Brawley O; Califf RM; Demets DL; Ellenberg SS; Kaplan RS
    Science; 2006 Apr; 312(5771):195. PubMed ID: 16614197
    [No Abstract]   [Full Text] [Related]  

  • 57. The United States Food and Drug Administration and the end of antibiotics.
    Shlaes DM; Moellering RC
    Clin Infect Dis; 2002 Feb; 34(3):420-2. PubMed ID: 11774094
    [No Abstract]   [Full Text] [Related]  

  • 58. Generic drug product equivalence: current status.
    Meyer MC
    Am J Manag Care; 1998 Aug; 4(8):1183-9; quiz 1190-2. PubMed ID: 10182892
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Laxative drug products for over-the-counter human use. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Jan; 64(19):4535-40. PubMed ID: 10557608
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A sad day for science at the FDA.
    Wood AJ; Drazen JM; Greene MF
    N Engl J Med; 2005 Sep; 353(12):1197-9. PubMed ID: 16141387
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.